Posted by Michael Wonder on 17 Sep 2024
Rozanolixizumab for the treatment of patients with generalised antibody positive myasthenia gravis
13 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use of rozanolixizumab in the NHS in England.
For the time being, rozanolixizumab is not recommended as an add-on to standard treatment for adults with generalised myasthenia gravis who test positive for anti-acetylcholine receptor antibodies or anti-muscle-specific tyrosine kinase antibodies.
